Is CD36 deficiency an etiology of hereditary hypertrophic cardiomyopathy?

Journal of Molecular and Cellular Cardiology

Volumn 29, Issue 1, 1997, Pages 121-127

  Tanaka, Takao ^a   Sohmiya, Koichi ^a   Kawamura, Keishiro ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Altered substrate utilization; CD36 deficiency; Hereditary hypertrophic cardiomyopathy; Long chain fatty acids

Indexed keywords

CD36 ANTIGEN; LONG CHAIN FATTY ACID;

ADULT; AGED; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC DISORDER; HEART MUSCLE; HEART MUSCLE PERFUSION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; PRIORITY JOURNAL;

EID: 0030971880     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1996.0257     Document Type: Article

References (44)

1. ABUMURAD NA, EL-MAGHRABI MR, AMRI E-Z, LOPEZ E, GRIMALDI PA, 1993. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. J Biol Chem 268: 17665-17668.
2. AMRI EZ, AILHAUD G, GRIMALDI PA, 1994. Fatty acids as signal transducing molecules: involvement in the differentiation of preadipose to adipose cells. J Lipid Res 35: 930-937.
3. BREMER J, OSMUNDSEN H, 1984. Fatty acid oxidation and its regulation. In: Numa S, ed., Fatty Acid Metabolism and Its Regulation. New York, Elsevier Science Publishers, 113-154.
4. BURCH HB, LOWRY OH, KUHLMAN AM, SHERJANER J, DIAMANT EJ, LAWRY SJ, VON DIPPLE P, 1963. Changes in patterns of enzymes of carbohydrate metabolism in the developing rat liver. J Biol Chem 238: 2267-2273.
5. CLARK CJ, 1971. Carbohydrate metabolism in the isolated fetal rat heart. Am J Physiol 220: 583-588.
6. CLARK JB, CLARK CMJ, 1982. The growth and metabolism of the developing heart. In: Colin, TJ ed. Biochemical Development of the Fetus and Neonate. New York, Elsevier Biomedical Press, 185-212.
7. CONSEVAGE MW, SALADA GC, BAYLEN BG, LADDA RL, ROGAN PK, 1994. A new missense mutation, Arg719GIn, in the beta-cardiac heavy chain myosin gene of patients with familial hypertrophic cardiomyopathy. Hum Mol Genet 3: 1025-1026.
8. FANANAPAZIR L, DALAKAS MC, CYRAN F, COHN G, EPSTEIN ND, 1993. Missense mutations in the beta-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 90: 3993-3997.
9. FRANK S, BRAUNWALD E, 1968. Idiopathic hypertrophic subaortic stenosis: clinical analysis of 126 patients with emphasis on the natural history. Circulation 37: 759-788.
10. GOODWIN JF, 1982. The frontiers of cardiomyopathy. Br Heart J 48: 1-18.
11. GREAVES SC, ROCHE AH, NEUTZE JM, WHITLOCK RM, VEALE AM, 1987. Inheritance of hypertrophic cardiomyopathy: a cross sectional and M mode echocardiographic study of 50 families. Br Heart J 58: 259-266.
12. GUTGESELL HP, MULLINS CE, GILLETTE PC, SPEER M, RUDOLPH AJ, MCNAMARA DG, 1976. Transient hypertrophic subaortic stenosis in infants of diabetic mothers. J Pediatr 89: 120-125.
13. GUTGESELL HP, SPEER ME, ROSENBERG HS, 1980. Characterization of the cardiomyopathy in infants of diabetic mothers. Circulation 61: 441-450.
14. HINA K, KUSACHI S, IWASAKI K, NOGAMI K, MORITANI H, KITA T, TANIGUCHI G, TSUJI T, 1993. Progression of left ventricular enlargement in patients with hypertrophic cardiomyopathy: incidence and prognostic value. Clin Cardiol 16: 403-407.
15. HUANG MM, BOLEN JB, BARNWELL JW, SHATTIL SJ, BRUGGE JS, 1991. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets. Proc Natl Acad Sci USA 88: 7844-7848.
16. a, involved in the refractoriness of HLA-matched platelet transfusion. Vox Sang 57: 213-217.
17. KURATA C, KOBAYASHI A, YAMAZAKI N, 1989. Dual tracer autoradiographic study with thallium-201 and radio-iodinated fatty acid in cardiomyopathic hamsters. J Nucl Med 30: 80-87.
18. KUSAKA Y, TANAKA T, OKAMOTO F, TERASAKI F, MATSUNAGA T, MIYAZAKI H, KAWAMURA K, 1995. Effect of sulfo-N-succinimidyl palmitate on the rat heart: myocardial long-chain fatty acid uptake and cardiac hypertrophy. J Mol Cell Cardiol 27: 1605-1612.
19. MANASEK FJ, 1970. Histogenesis of the embryonic myocardium. Am J Cardiol 25: 149-168.
20. MARIAN AJ, KELLY D, MARES AJ, FITZGIBBONS J, CAIRA T, QUN T, HILL R, PERRYMAN MB, ROBERTS R, 1994. A missense mutation in the beta myosin heavy chain is a predictor of premature sudden death in patients with hypertrophic cardiomyopathy. J Sports Med Phys Fitness 34: 1-10.
21. MARON BJ, VERTER J, 1978. Disproportionate ventricular septal thickening in the developing normal human heart. Circulation 57: 520-526.
22. MARON BJ, EPSTEIN SE, ROBERTS WC, 1979a. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant athrosclerosis of the extramural coronary arteries. Am J Cardiol 43: 1086-1102.
23. MARON BJ, SATO N, ROBERTS WC, EDWARDS JE, CHANDRA RS, 1979b. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum. Comparison of fetuses and infants with and without congenital heart disease and patients with hypertrophic cardiomyopathy. Circulation 60: 685-696.
24. MARON BJ, NICHOLS PFI, PICKLE LW, WESLEY TE, MULVIHILL JJ. 1984. Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and two-dimensional echocardiography. Am J Cardiol 53: 1087-1094.
25. MCKENNA WJ, GOODWIN JF, 1981. The natural history of hypertrophic cardiomyopathy. Curr Probl Cardiol 6: 1-26.
26. PERLOFF JK, 1981. Pathogenesis of hypertrophic cardiomyopathy: hypothesis and speculation. Am Heart J 101: 219-226.
27. RUPP H, ELIMBAN V, DHALLA NS, 1988. Sucrose feeding prevents changes in myosin isoenzymes and sarcoplasmic reticulum Ca2 +-pump ATPase in pressure-loaded rat heart. Biochem Biophys Res Commun 156: 917-923.
28. RUPP H, JACOB R, DHALLA NS, 1990. Signal transduction in myocardial hypertrophy and myosin expression. In: Korecky B, Dhalla NS, eds, Subcellular Basis of Contractile Failure. Boston, MA, Kluwer Academic Publishers, 135-154.
29. RUPP H, ELIMBAN V, DHALLA NS, 1992. Modification of subcellular organelles in pressure-overloaded heart by etomoxir, a carnitine palmitoyltransferase I inhibitor. FASEB J 6: 2349-2353.
30. SAUNDUBRAY J, MITCHELL G, BONNEFONT J, SCHWARTZ G, NUTTIN C, MUNNICH A, BRIVET M, VASSAULT A, DEMAUGRE F, RABIER D, CHARPENTIER C, 1992. Approach to the patient with a fatty acid oxidation disorder. In: Coates PM, Tanaka K, eds, New developments in fatty acid oxidation. Progress in Clinical and Biological Research Vol. 375, New York, Wiley-Liss, 271-288.
31. SCHAFFER JE, LODISH HF, 1994. Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. Cell 79: 427-436.
32. SPIRITO P, CHIARELLA F, CARRATINO L, BERISSO M, BELLOTTI P, VECCHIO C, 1989. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 320: 749-755.
33. STREMMEL W, 1988. Fatty acid uptake by isolated rat heart myocytes represents a carrier-mediated transport process. J Clin Invest 81: 844-852.
34. TAKEISHI Y, CHIBA J, ABE S, TONOOKA I, KOMATANI A, TOMOIKE H, 1992. Heterogeneous myocardial distribution of iodine-12315-(p-iodophenyl)-3-R, S-methylpentadecanoic acid (BMIPP) in patients with hypertrophic cardiomyopathy. Eur J Nucl Med 19: 775-782.
35. TANAKA T, KAWAMURA K, 1995. Isolation of myocardial membrane long-chain fatty acid-binding protein: homology with a rat membrane protein implicated in the binding or transport of long-chain fatty acids. J Mol Cell Cardiol 27: 1613-1622.
36. a, on platelet membrane glycoprotein IV. Blood 75: 684-687.
37. VAN NIEUWENHOVEN FA, VERSTIJNEN CP, ABUMRAD NA, WILLEMSEN PH, VAN EYS GJ, VAN DER VUSSE GJ, GLATZ JF, 1995. Putative membrane fatty acid translocase and cytoplasmic fatty acid-binding protein are co-expressed in rat heart and skeletal muscles. Biochem Biophys Res Commun 207: 747-752.
38. WATKINS H, ANAN R, COVIELLO DA, SPIRITO P, SEIDMAN JG, SEIDMAN CE, 1995a. A de novo mutation in alpha-tropomyosin that causes hypertrophic cardiomyopathy. Circulation 91: 2302-2305.
39. WATKINS H, MCKENNA WJ, THIERFELDER L, SUK HJ, ANAN R, O'DONOGHUE A, SPIRITO P, MATSUMORI A, MORAVEC CS, SEIDMAN JG, et al 1995b. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 332: 1058-1064.
40. WAY GL, WOLFE RR, ESHAGHPOUR E, BENDER RL, JAFFE RB, RUTTENBERG HD, 1979. The natural history of hypertrophic cardiomyopathy in infants of diabetic mothers. J Pediatr 95: 1020-1025.
41. WIGLE ED, SASSON Z, HENDERSON MA, RUDDY TD, FULOP J, RAKOWSKI H, WILLIAMS WG, 1985. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 28: 1-83.
42. YAMAMOTO N, IKEDA H, TANDON NN, HERMAN J, TOMIYAMA Y, MITANI T, SEKIGUCHI S, LIPSKY R, KRALISZ U, JAMIESON GA, 1990. A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: nakaplatelets lack detectable GPIV (CD36). Blood 76: 1698-1703.
43. YAMAMOTO N, AKAMATSU N, YAMAZAKI H, TANOUE K, 1992. Normal aggregations of glycoprotein IV (CD36)-deficient platelets from seven healthy Japanese donors. Br J Haematol 81: 86-92.
44. YAMAMOTO N, AKAMATSU N, SAKURABA H, YAMAZAKI H, TANOUE K, 1994. Platelet glycoprotein IV (CD36) deficiency is associated with the absence (type I) or the presence (type II) of glycoprotein IV on monocytes. Blood 83: 392-397.